TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198

Key Points

• Focal segmental glomerulosclerosis treatment improved significantly with TRPC6 inhibition.
• The phase 2 trial observed a notable reduction in proteinuria, a key marker of kidney damage.
• Randomised placebo-controlled trial setup enhances the reliability of outcomes and findings.
• These results suggest promising therapeutic avenues while underscoring the need for further validation.